Moderna's stock surged 8% in a single day despite no new announcements, regulatory decisions, or clinical trial updates to justify the move. This rally comes after a 143% gain over the past month, largely driven by positive results from its personalized cancer vaccine trial with Merck. The biotech sector and Moderna's peers like BioNTech remained flat or declined, indicating the surge is specific to Moderna and likely driven by momentum trading or short covering rather than fundamental news. Investors should watch if the gain holds or fades and consider upcoming clinical or regulatory milestones before buying at these elevated levels.
Moderna's stock dropped sharply by over 21% in two days following the leak of early Phase 3 trial results for its personalized cancer vaccine and a major downgrade from Citi, which issued a 'Sell' rating and an $80 price target. Despite the leaked re...
Moderna's stock fell up to 25% following the leak of partial data on its cancer vaccine developed with Merck, despite the full phase 3 trial results later showing positive outcomes. The vaccine, combined with Merck's Keytruda, reduced the risk of mel...
Moderna's stock fell sharply by 25% following an unauthorized leak of Phase 3 data for its experimental cancer vaccine developed with Merck. The data was expected to be officially presented at a medical conference this weekend. Merck's shares also de...
Moderna's stock dropped 25% after a late-stage melanoma vaccine report was briefly posted online and then removed. The vaccine, developed with Merck, showed favorable results in reducing melanoma recurrence or death when combined with Keytruda, but t...
Moderna, known for its mRNA COVID-19 vaccine, is set to reveal full Phase 3 data for its experimental cancer vaccine targeting melanoma. The results, expected this weekend, could mark a breakthrough in cancer treatment using customized mRNA technolog...
